The First Affiliated Hospital of Xiamen University
🇨🇳China
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Phase 3
Not yet recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Target Recruit Count
- 37
- Registration Number
- NCT06188455
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Phase 2
Recruiting
- Conditions
- Follicular LymphomaRefractory B-Cell LymphomaRelapsed Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2025-02-19
- Target Recruit Count
- 33
- Registration Number
- NCT06158386
- Locations
- 🇨🇳
Bing Xu, Xiamen, Fujian, China
AZA Combined With RCHOP in P53-mutated DLBCL.
Phase 2
Recruiting
- Conditions
- TP53DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2025-02-19
- Target Recruit Count
- 52
- Registration Number
- NCT06158399
- Locations
- 🇨🇳
Bing Xu, Xiamen, Fujian, China
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Multiple Myeloma, RefractoryMultiple Myeloma in Relapse
- Interventions
- Drug: All-trans Retinoic Acid in combination with the KPD Regimen
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2025-02-19
- Target Recruit Count
- 25
- Registration Number
- NCT06158412
- Locations
- 🇨🇳
Bing Xu, Xiamen, Fujian, China
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Phase 2
Recruiting
- Conditions
- Follicular LymphomaDLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-02-19
- Target Recruit Count
- 38
- Registration Number
- NCT06151080
- Locations
- 🇨🇳
Bing Xu, Xiamen, Fujian, China
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Phase 2
Recruiting
- Conditions
- Peripheral T Cell LymphomaRefractory T-Cell LymphomaRelapsed Peripheral T-Cell Lymphoma
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-02-19
- Target Recruit Count
- 33
- Registration Number
- NCT06151106
- Locations
- 🇨🇳
The First Affiliated Hosptial of Xiamen University, Xiamen, Fujian, China
68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
Recruiting
- Conditions
- Primary Myelofibrosis
- Interventions
- Diagnostic Test: 68Ga FAPI PET/CT
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-02-19
- Target Recruit Count
- 90
- Registration Number
- NCT06151119
- Locations
- 🇨🇳
Bing Xu, Xiamen, Fujian, China
Mobile Internet Healthcare and Three Disciplines Co-management Intervention for Overweight/Obese Prediabetic Patients
Not Applicable
Recruiting
- Conditions
- Overweight/ObesityPrediabetesWeight Management
- Interventions
- Behavioral: mobile internet healthcare and "co-management of three disciplines"
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2023-11-28
- Target Recruit Count
- 100
- Registration Number
- NCT06147752
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Difference Between Mean Gestational Sac Diameter and Crown-rump Length as a Marker of First-trimester Pregnancy Outcome in Patients With Recurrent Spontaneous Abortion
Completed
- Conditions
- Recurrent Spontaneous Abortion
- Interventions
- Diagnostic Test: ultrasonic testing
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-10-13
- Target Recruit Count
- 256
- Registration Number
- NCT06081556
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Graves' Disease Remission Study: MycoMeth Combo
Phase 2
Recruiting
- Conditions
- Graves' Disease
- Interventions
- Drug: methimazole, oral, 10mg
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-02-28
- Target Recruit Count
- 205
- Registration Number
- NCT06068179
- Locations
- 🇨🇳
Xiao Fangsen, Xiamen, Fujian, China